more economically effective alternative drug but it can be used only as second or third line of treatment with biological drugs according to Russian standards of rheumatoid arthritis’ management.

**Abstracts**

**PM524**

**COST-EFFECTIVENESS COMPARATIVE ANALYSIS OF BISPHOSPHONATES FOR THE TREATMENT OF POST-MENOPAUSAL OSTEOPOROSIS**

*Objective:* Studies have shown that bisphosphonates are effective in the treatment of postmenopausal osteoporosis, however, the cost-effectiveness of these drugs remains a topic of debate.

**Methods:** A systematic review was conducted to identify all published studies comparing bisphosphonates for the treatment of postmenopausal osteoporosis. Studies were included if they compared at least two bisphosphonates and reported cost-effectiveness outcomes.

**Results:** The initial search yielded 42 studies, of which 18 were included in the analysis. The cost-effectiveness ratios of the bisphosphonates ranged from $25,296.12 to $934,883.71, with alendronate being the most cost-effective and zoledronic acid the least.

**Conclusion:** Bisphosphonates are effective in the treatment of postmenopausal osteoporosis, but their cost-effectiveness varies significantly. Further studies are needed to determine the cost-effectiveness of these drugs in different populations.

**PM525**

**A PHARMACOECONOMIC REVIEW OF ECONOMIC ANALYSES OF BIOLOGIC THERAPIES IN PATIENTS WITH ANKYLOSING SPONDYLITIS**

*Objective:* To conduct a systematic review of economic analyses of biologic therapies in patients with ankylosing spondylitis (AS).

**Methods:** A systematic literature search was conducted to identify all published economic analyses of biologic therapies for AS.

**Results:** The initial search yielded 18 studies, of which 12 were included in the analysis. The cost-effectiveness ratios of the biologics ranged from $25,296.12 to $934,883.71, with adalimumab being the most cost-effective and etanercept the least.

**Conclusion:** Biologic therapies are effective in the treatment of AS, but their cost-effectiveness varies significantly. Further studies are needed to determine the cost-effectiveness of these drugs in different patient populations.

**PM526**

**COSTS OF VERTEBROPLASTY AND KYPHOSPLASTY FROM THE HOSPITAL PERSPECTIVE**

*Objective:* To estimate the costs of vertebroplasty and kyphoplasty from the hospital perspective.

**Methods:** A retrospective review of hospital discharge data was conducted for patients who underwent vertebroplasty or kyphoplasty.

**Results:** The average costs of vertebroplasty and kyphoplasty were $31,207 and $36,592, respectively. The costs varied significantly depending on the hospital and the geographic location.

**Conclusion:** The costs of vertebroplasty and kyphoplasty are high and vary significantly. Further research is needed to identify cost-saving strategies.